Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06100770 · ClinicalTrials.gov registry record
Aveir AR Coverage With Evidence Development (CED) Study
A clinical trial of Bradycardia and Arrhythmia, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- 586
- Enrollment target
- 1
- Study location
NCT06100770: Recruiting study of Bradycardia and Arrhythmia, sponsored by Abbott Medical Devices.
NCT06100770 is a study of Bradycardia and Arrhythmia that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 586 participants, below the 4,393-participant average among 29 other Bradycardia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06100770, a study of Bradycardia and Arrhythmia, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- 586 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).
Primary Outcome
Assess the acute (30-day) complication rate of the Aveir AR LP, compared to single chamber atrial transvenous pacemakers. An acute complication is defined as a peri-procedural, device-related adverse event occurring within 30 days post-implant.
Conditions Studied
Interventions
- DEVICE Aveir AR Leadless Pacemaker
- DEVICE Single-chamber atrial transvenous pacemaker
Study Locations (1)
California
- Abbott - Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2031-01 |
What NCT06100770 shows while recruiting
NCT06100770 is an observational study that tracks outcomes without assigning an intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, below the 4,393-participant average among 29 other Bradycardia trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Bradycardia appearing as the primary indexed condition, and to 2 interventions - of which Aveir AR Leadless Pacemaker is the first listed.
NCT06100770 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06100770 about?
NCT06100770 is a clinical study titled "Aveir AR Coverage With Evidence Development (CED) Study". The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).
What is the current status of trial NCT06100770?
This trial is currently recruiting. The enrollment target is 586 participants. The study started on 2024-01-18. Estimated completion is 2031-01.
What conditions does trial NCT06100770 study?
This clinical trial studies the following conditions: Bradycardia, Arrhythmia, Cardiac Pacemaker.
What interventions are being tested in trial NCT06100770?
The interventions under investigation include: Aveir AR Leadless Pacemaker (DEVICE), Single-chamber atrial transvenous pacemaker (DEVICE).
Who is sponsoring clinical trial NCT06100770?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06100770 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bradycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06100770's enrollment target sits among peer trials
586 16th of 29 higher than 14 of 29 other Bradycardia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bradycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants
RECRUITING · NA
-
Aveir VR Real-World Evidence Post-Approval Study
RECRUITING
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RECRUITING
-
The Alaska Oculocardiac Reflex Study
RECRUITING
-
His Bundle Pacing in Bradycardia and Heart Failure
RECRUITING
-
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT06976203 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- NCT06976216 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI